Editorial: Incretin agonists in the treatment of obesity
Source : https://www.frontiersin.org/articles/10.3389/fendo.2023.1265826/full
Obesity has emerged as a critical global public health concern over the past decade.Studies have demonstrated that even a modest weight reduction significantly decreases the risk of developing obesity-related complications...
Conclusions: Overall, the escalating prevalence of obesity presents a pressing global health challenge. The articles presented with the Research Topic highlight the crucial role of various incretin agonists in weight reduction and improvement of cardiometabolic profiles. Nevertheless, ongoing research is vital to refine and expand the arsenal...
Share
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis - Cardiovascular Diabetology
Source : https://cardiab.biomedcentral.com/articles/10.1186/s12933-023-01949-7
Background Semaglutide is a glucose-lowering treatment for type 2 diabetes (T2D) with demonstrated cardiovascular benefits; semaglutide may also have kidney-protective effects. This post hoc analysis investigated the association between major...
Conclusions: MACE risk was greater for participants with kidney impairment or damage than for those without. Semaglutide consistently reduced MACE risk across eGFR and UACR subgroups, indicating that semaglutide provides cardiovascular benefits in people with T2D and at high cardiovascular risk across a broad spectrum of kidney function and...
Share
The role of weight control in the management of type 2 diabetes mellitus: Perspectives on semaglutide - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37591343/
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used to address multiple aspects of type 2 diabetes mellitus (T2DM) management, including glycaemic control, weight loss, and cardiovascular risk reduction. Semaglutide,...
Conclusions/Relevance: Thus, semaglutide offers a well-established therapeutic option that aligns well with guideline recommendations for T2DM management, emphasizing the high importance of weight control and amelioration of other cardiometabolic risk factors.
Share
Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37541792/
The LiRa_NL group showed the most weight loss, although the discontinuation rate was high. Most side-effects occurred at 1-2 months. When prescribing GLP-1 RA, education concerning side-effects and discontinuation is...
Conclusions: The LiRa_NL group showed the most weight loss, although the discontinuation rate was high. Most side-effects occurred at 1–2 months. When prescribing GLP-1 RA, education concerning side-effects and discontinuation is needed to enhance treatment adherence.
Share
Semaglutide and cancer: A systematic review and meta-analysis
Source : https://www.sciencedirect.com/science/article/abs/pii/S1871402123001303?via=ihub
French national health care insurance system database has suggested 1-3 years use of glucagon like peptide-1 receptor agonists (GLP1RA) (exenatide, li...
Conclusion: Semaglutide use in RCTs and real-world studies was not associated with an increased risk of any types of cancer, and this conclusion is supported by a high grade of evidence.
Share